TR200003779T2 - Transcription factor NF-kB inhibitors - Google Patents

Transcription factor NF-kB inhibitors

Info

Publication number
TR200003779T2
TR200003779T2 TR2000/03779T TR200003779T TR200003779T2 TR 200003779 T2 TR200003779 T2 TR 200003779T2 TR 2000/03779 T TR2000/03779 T TR 2000/03779T TR 200003779 T TR200003779 T TR 200003779T TR 200003779 T2 TR200003779 T2 TR 200003779T2
Authority
TR
Turkey
Prior art keywords
inhibitors
disease
diseases
amino
transcription factor
Prior art date
Application number
TR2000/03779T
Other languages
Turkish (tr)
Inventor
Francis Callahan James
C.Chabot-Fletcher Marie
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200003779T2 publication Critical patent/TR200003779T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

Bu bulus, trankripsiyon faktörü NF-kB nin farmasötik olarak kabul edilebilir tuzlari, hidratlari ve solventlerinin amino-indanon inhibitörlerini, bu bilesimlerin terkiplerini ve NF-kB aktivasyonunun rol oyandigi hastaliklari tedavi yöntemleri saglamaktadir. Bu bulus özellikle örnegin enflamatuar hastaliklarin, özellikle romatizmal artrit, enflamatuar barsak hastaligi, ve astim; sedef hastaligi ve atopik dermatil dahil, dermatoz; oto-immün hastaliklar; doku ve organ reddi; alzheimer hastaligi; felç; ateroskleroz; restenoz; kanser ve Hodojken hastaligi; bazi viral enfeksiyonlar, AIDS dahil; osteoartrit; osteoporoz; ve Ataxia Telangiestasia gibi NF-kB aktivasyonuyla baglantili çesitli hastaliklarin, ihtiyaci olan hastaya bir bulus bilesimi verilmesi için yöntemler saglar.This invention provides pharmaceutically acceptable salts, hydrates and amino-indanon inhibitors of the transcription factor NF-kB, amino-indanone inhibitors of these compounds, and methods of treating diseases in which NF-kB activation plays a role. This invention is particularly useful in, for example, inflammatory diseases, especially rheumatic arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatil; autoimmune diseases; tissue and organ rejection; alzheimer's disease; paralysis; atherosclerosis; restenosis; cancer and Hodojken disease; some viral infections, including AIDS; osteoarthritis; osteoporosis; and various diseases associated with NF-kB activation, such as Ataxia Telangiestasia, to provide a combination of findings to the patient in need.

TR2000/03779T 1998-06-19 1999-06-18 Transcription factor NF-kB inhibitors TR200003779T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9001698P 1998-06-19 1998-06-19

Publications (1)

Publication Number Publication Date
TR200003779T2 true TR200003779T2 (en) 2001-06-21

Family

ID=22220761

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03779T TR200003779T2 (en) 1998-06-19 1999-06-18 Transcription factor NF-kB inhibitors

Country Status (17)

Country Link
EP (1) EP1085872A4 (en)
JP (1) JP2002518333A (en)
KR (1) KR20010052990A (en)
CN (1) CN1306428A (en)
AR (1) AR019871A1 (en)
AU (1) AU4699699A (en)
BR (1) BR9911151A (en)
CA (1) CA2335293A1 (en)
CO (1) CO5080752A1 (en)
CZ (1) CZ20004760A3 (en)
HU (1) HUP0102492A2 (en)
IL (1) IL140324A0 (en)
NO (1) NO20006452L (en)
PL (1) PL345577A1 (en)
TR (1) TR200003779T2 (en)
WO (1) WO1999065495A1 (en)
ZA (1) ZA200007448B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0951551B9 (en) 1996-12-23 2012-12-26 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
DE69939822D1 (en) 1998-05-14 2008-12-11 Immunex Corp METHOD FOR INHIBITING THE EFFECT OF OSTEOCLASTICS
JP5512909B2 (en) * 2000-01-24 2014-06-04 ジェンザイム・コーポレーション JAK / STAT pathway inhibitors and uses thereof
US20060148732A1 (en) * 2000-11-17 2006-07-06 Gutterman Jordan U Inhibition of NF-kappaB by triterpene compositions
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
WO2007097981A2 (en) 2006-02-16 2007-08-30 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
PL2366699T3 (en) 2008-10-02 2013-12-31 Asahi Kasei Pharma Corp 8-substituted isoquinoline derivative and use thereof
WO2010108058A2 (en) * 2009-03-20 2010-09-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Small molecule inhibitors of dusp6 and uses therefor
EP2461806A4 (en) * 2009-07-31 2012-12-26 Us Health Antiangiogenic small molecules and methods of use
US10160705B2 (en) 2011-02-10 2018-12-25 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US9670236B2 (en) 2012-10-31 2017-06-06 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

Also Published As

Publication number Publication date
EP1085872A1 (en) 2001-03-28
WO1999065495A1 (en) 1999-12-23
AU4699699A (en) 2000-01-05
JP2002518333A (en) 2002-06-25
CN1306428A (en) 2001-08-01
CA2335293A1 (en) 1999-12-23
NO20006452L (en) 2001-02-16
NO20006452D0 (en) 2000-12-18
CZ20004760A3 (en) 2001-08-15
HUP0102492A2 (en) 2001-11-28
IL140324A0 (en) 2002-02-10
CO5080752A1 (en) 2001-09-25
ZA200007448B (en) 2001-12-12
BR9911151A (en) 2001-03-06
EP1085872A4 (en) 2003-04-16
AR019871A1 (en) 2002-03-20
PL345577A1 (en) 2001-12-17
KR20010052990A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
TR200003781T2 (en) Transcription factor NF-kB inhibitors
HK1051691A1 (en) Hydroxylstilbenes and stilbene derivatives and analogues of anti-inflammatory and psoriasis treatment and protein kinase inhibition
TR200003779T2 (en) Transcription factor NF-kB inhibitors
PT1115701E (en) ARILSULFONANILIDA UREES
DE602005016718D1 (en) Ä1,2,4ÜTRIAZOLOÄ4,3-AÜPYRIDIN DERIVATIVE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
DE69724811D1 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
BR0112857A (en) 2- (4-Pyridyl) amino-6-dialkoxyphenyl-pyrido- [2,3-d] pyrimidin-7-ones compounds
MY138352A (en) Benzothiazole derivatives
TR199801195T2 (en) Quinoline and quinosil compounds useful in therapy.
NO995543D0 (en) Mono esters from probucol for the treatment of cardiovascular and inflammatory disease
IS6852A (en) compounds
BR0111544A (en) 6.5-fused bicyclic heterocycles
BRPI0415185A (en) 2h- [1,2,4] triazole [4,3-a] substituted pyrazines as gsk-3 inhibitors
DE60233239D1 (en) benzothiazepine derivatives
ES2118557T3 (en) ISOXAZOLINE COMPOUNDS AS INHIBITORS OF TNF RELEASE.
PT1049703E (en) N-2- (5-BENZYLOXYCARBONYLAMINO-6-OXO-2- (4-FLUOROPHENYL) -1,6-DIHYDRO-1-PYRIMIDINYL) ACETOXYL-ASPARTIC ACID AS INHIBITOR OF THE INVENTION INTERLEUCINA-1BETA IN VIVO
NO20062599L (en) Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
ATE380174T1 (en) ARGININE MIMETICS AS FACTOR XA INHIBITORS
EA200000921A1 (en) ANTAGONISTS OF THE VITRONECTIN RECEPTOR
ATE327242T1 (en) NEW PURINES
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
AP2000001761A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
NZ330944A (en) Peptide derivatives
ATE266029T1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATORY
DK0804465T3 (en) New elastase inhibitors